These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26020268)

  • 1. Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types.
    Amend SR; Wilson WC; Chu L; Lu L; Liu P; Serie D; Su X; Xu Y; Wang D; Gramolini A; Wen XY; O'Neal J; Hurchla M; Vachon CM; Colditz G; Vij R; Weilbaecher KN; Tomasson MH
    PLoS One; 2015; 10(5):e0127828. PubMed ID: 26020268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAMSN1 is a tumor suppressor gene in multiple myeloma.
    Noll JE; Hewett DR; Williams SA; Vandyke K; Kok C; To LB; Zannettino AC
    Neoplasia; 2014 Jul; 16(7):572-85. PubMed ID: 25117979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
    Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
    Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma in the marrow: pathogenesis and treatments.
    Fairfield H; Falank C; Avery L; Reagan MR
    Ann N Y Acad Sci; 2016 Jan; 1364(1):32-51. PubMed ID: 27002787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
    Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
    Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
    Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
    J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
    Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
    Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
    Fowler JA; Mundy GR; Lwin ST; Edwards CM
    Cancer Res; 2012 May; 72(9):2183-9. PubMed ID: 22374979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial genome of a spontaneous multiple myeloma bone cancer model mouse C57BL/KaLwRij strain.
    Liu ZG; Tang B; Zeng Y; He N; Wang ZY; Han H; Wang L; Wang TZ; Yu HL; Xiong M
    Mitochondrial DNA A DNA Mapp Seq Anal; 2016 Nov; 27(6):4071-4072. PubMed ID: 25693717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.
    Purushothaman A; Toole BP
    J Biol Chem; 2014 Feb; 289(9):5499-509. PubMed ID: 24403068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.
    Michigami T; Shimizu N; Williams PJ; Niewolna M; Dallas SL; Mundy GR; Yoneda T
    Blood; 2000 Sep; 96(5):1953-60. PubMed ID: 10961900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration.
    Kristensen IB; Pedersen L; Rø TB; Christensen JH; Lyng MB; Rasmussen LM; Ditzel HJ; Børset M; Abildgaard N
    Eur J Haematol; 2013 Sep; 91(3):196-200. PubMed ID: 23607294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo.
    Opperman KS; Vandyke K; Clark KC; Coulter EA; Hewett DR; Mrozik KM; Schwarz N; Evdokiou A; Croucher PI; Psaltis PJ; Noll JE; Zannettino AC
    Neoplasia; 2019 Aug; 21(8):777-787. PubMed ID: 31247457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma.
    Zojer N; Ludwig H; Fiegl M; Stevenson FK; Sahota SS
    Blood; 2003 May; 101(10):4137-9. PubMed ID: 12531815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.
    Menu E; Asosingh K; Indraccolo S; De Raeve H; Van Riet I; Van Valckenborgh E; Vande Broek I; Fujii N; Tamamura H; Van Camp B; Vanderkerken K
    Haematologica; 2006 May; 91(5):605-12. PubMed ID: 16627256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.
    Oben B; Froyen G; Maclachlan KH; Leongamornlert D; Abascal F; Zheng-Lin B; Yellapantula V; Derkach A; Geerdens E; Diamond BT; Arijs I; Maes B; Vanhees K; Hultcrantz M; Manasanch EE; Kazandjian D; Lesokhin A; Dogan A; Zhang Y; Mikulasova A; Walker B; Morgan G; Campbell PJ; Landgren O; Rummens JL; Bolli N; Maura F
    Nat Commun; 2021 Mar; 12(1):1861. PubMed ID: 33767199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
    Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
    Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice.
    Friend N; Noll JE; Opperman KS; Clark KC; Mrozik KM; Vandyke K; Hewett DR; Zannettino ACW
    PLoS One; 2020; 15(1):e0228408. PubMed ID: 31995627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis.
    Gámez B; Edwards CM
    Curr Osteoporos Rep; 2018 Dec; 16(6):635-641. PubMed ID: 30229522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of alpha-smooth muscle actin in the stromal cells of bone marrow in fetuses in different stages of development, in multiple myeloma and monoclonal gammopathy of unknown significance.
    Tamiolakis D; Kotini A; Lambropoulou M; Tolparidou I; Papadopoulos N
    Clin Exp Obstet Gynecol; 2002; 29(1):45-8. PubMed ID: 12013093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.